Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Servier Pharmaceuticals LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners across 3 distinct art units, indicating prosecution activity spread across several examination contexts.
KOMATSU, LI N is the busiest examiner, with 1 pending matter. Counsel should manage each matter independently while preserving consistency in pharmaceutical claim scope, supporting evidence, and overall portfolio positioning.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | CHICKS, ASHLI ARIANA | 4d overdue |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | ROBINSON, MIKHAIL O'DONNEL | 34d |
| 18111511 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | KOMATSU, LI N | — |
| 18015396 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1658 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18111511 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | KOMATSU, LI N | 1658 | DP | Non-Final OA | — | Pending | Feb 17, 2023 |
| 18015396 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | HERNANDEZ, JACKSON J | 1627 | §103Other | Non-Final OA | — | Pending | Jan 10, 2023 |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§103DP | Final Rejection | 34d | Pending | Nov 07, 2022 |
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | CHICKS, ASHLI ARIANA | 1626 | §103DP | Non-Final OA | 4d overdue | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialServier Pharmaceuticals LLC has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Li N Komatsu has the most, with 1 of Servier Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
